AGL INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of agilon health
newsfilecorp.com
Want to monitor RARE?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor RAREultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics.